- Home
- BLFS vs ORIC Comparison
BLFS vs ORIC Comparison
Compare BLFS & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLFS | ORIC |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United States |
| Employees | N/A | 104 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 923.5M | 861.3M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BLFS | ORIC |
|---|---|---|
| Price | $24.01 | $8.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | ★ $32.00 | $19.73 |
| AVG Volume (30 Days) | 429.0K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.27 | 19.67 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $96,214,000.00 | N/A |
| Revenue This Year | $19.73 | N/A |
| Revenue Next Year | $17.82 | N/A |
| P/E Ratio | $1,235.25 | ★ N/A |
| Revenue Growth | ★ 16.97 | N/A |
| 52 Week Low | $17.86 | $5.51 |
| 52 Week High | $29.57 | $14.93 |
Technical Indicators
Market Signals| Indicator | BLFS | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 62.58 | 37.06 |
| Support Level | $23.74 | $7.90 |
| Resistance Level | $26.55 | $11.22 |
| Average True Range (ATR) | 1.19 | 0.44 |
| MACD | 0.27 | -0.01 |
| Stochastic Oscillator | 77.08 | 30.75 |
Price Performance
Historical ComparisonAbout BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.